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In this issue of HEPATOLOGY, Mathurin et al. report the
results of a 10-year retrospective study of kidney transplant
recipients that compared rates of patient and graft survival
among patients with and without chronic hepatitis B virus
(HBV) or hepatitis C virus (HCV) infection.1 Following this
cohort of patients at intervals of 5 and 10 years, the
investigators found a statistically significant decrease in
survival in the HBV-infected group at both 5 and 10 years and
a similar decrease at 10 years in the HCV-infected group. The
findings of this study underscore the importance of prevent-
ing these infections in end-stage renal disease patients.
End-stage renal disease patients on chronic hemodialysis
are at risk for both HBV and HCV infection.2,3 HBV is the
most efficiently transmitted blood-borne virus in the hemodi-
alysis setting. Outbreak investigations and other studies have
consistently shown that risk factors associated with HBV
transmission among hemodialysis patients include the pres-
ence of a chronically infected patient; failure to separate that
patient by room, machine, and staff; and failure to vaccinate
patients against hepatitis B.4-6 After the 1977 publication of
specific infection control practices for controlling HBV infec-
tion in chronic hemodialysis units (i.e., hemodialysis unit
precautions),7 the incidence of HBV infections in these
patients decreased dramatically.4,5 These practices included
(1) monthly serological testing for hepatitis B surface antigen
(HBsAg) of all susceptible patients and prompt review of
results; (2) glove use whenever patients or hemodialysis
equipment are touched; (3) the assignment of specific nondis-
posable items to individual patients so that no sharing of
instruments, medications, and supplies between any patients
occurred, regardless of serological status; and (4) separation
of clean and contaminated areas, such that handling and
storage of medications and hand washing are not done in the
same or an adjacent area to that where blood samples or used
equipment are handled. Other routine precautions recom-
mended for all hemodialysis patients included the assign-
ment of patients to specific dialysis stations and cleaning or
disinfecting nondisposable items and environmental surfaces
between uses. In addition, the recommended precautions for
HBsAg-positive patients required the physical separation of
these patients from susceptible patients and the cohorting of
separate dialysis machines, instruments, supplies, and staff to
HBsAg-positive patients.
In 1982, hepatitis B vaccination was recommended for all
susceptible patients and staff in hemodialysis units.2 Al-
though hepatitis B vaccination produces lower immunogenic-
ity rates in hemodialysis patients than in healthy persons, half
or more of hemodialysis patients can be protected from
hepatitis B by vaccination, and maintaining immunity among
these patients reduces the frequency and costs of serological
screening.2,8 Higher rates of protection can be achieved by
vaccinating end-stage renal disease patients before they begin
dialysis.9
Despite the success of long-standing infection control
practices for preventing HBV infections among chronic
hemodialysis patients, HBV transmission in this setting
remains problematic. Recently, five hepatitis B outbreaks in
chronic hemodialysis units were reported during 1 year in the
United States.10 Investigations indicated that all resulted from
failure to use recommended infection control practices,
including failure to routinely screen patients for HBsAg or
routinely review results of testing to detect infected patients;
assignment of staff to the simultaneous care of infected and
susceptible patients; and sharing of supplies, particularly
multidose medication vials, among patients. In addition, few
patients in these units had received hepatitis B vaccine, and
overall, only 36% of patients in the United States have ever
received the vaccine.5
It is not clear why, after 20 years of successful implementa-
tion of infection control strategies in the hemodialysis setting
that resulted in the near eradication of new HBV infections
among patients and staff, these strategies are no longer fully,
or universally implemented. Changes in staffing patterns,
downsizing of staff, and lack of knowledge or understanding
of appropriate infection control practices and the merits of
vaccination in this setting might all be contributing factors.11
Alternatively, the emphasis on ‘‘universal precautions’’ (now
referred to as standard precautions) in the mid 1980s might
have caused hemodialysis staff to focus only on barrier
precautions for preventing transmission, whereas the precau-
tions unique to the hemodialysis environment that are
essential for preventing patient-to-patient transmission of
HBV and other blood-borne pathogens in this setting were
minimized or forgotten.
Standard precautions focus on barrier precautions to
prevent exposure to blood-borne pathogens, and include
directions for hand washing after touching blood and other
potentially infectious material, the wearing of gloves when
touching blood or other potentially infectious material, and
the wearing of face shields and gowns when exposure to
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blood or body fluids was anticipated. Standard precautions do
not restrict the use of supplies, instruments, and medications
to a single patient. Routine precautions for hemodialysis
units are more stringent than standard precautions.
Routine hemodialysis unit precautions, regardless of pa-
tients’ serological status, require glove use whenever patients
or hemodialysis equipment are touched and specify that no
supplies, instruments, or medications be shared between any
patients, including ancillary supply equipment such as trays,
blood pressure cuffs, clamps, scissors and other nondispos-
able items. Other precautions specific to the hemodialysis
environment include preparing and distributing medications
from a centralized area and not using common medication
and supply carts so that the practice of sharing of medications
and supplies is eliminated.
Routine hemodialysis unit precautions should be sufficient
for preventing transmission of HBV among hemodialysis
patients, when such practices are routinely and rigorously
performed. Unfortunately, such is not the case in many
hemodialysis units, as shown by recent outbreaks of HBV
infection. In most instances, ‘‘minor’’ breaks in infection
control practices will not result in blood-borne pathogen
transmission, because the pathogens might not be present,
the dose might be insufficient to result in infection, or the
pathogens do not survive on environmental surfaces. How-
ever, HBV circulates at extraordinarily high titers and remains
stable on environmental surfaces for long periods of time,12,13
thus, even ‘‘minor’’ accidental breaks in infection control
practices can result in HBV transmission among patients.
Therefore, the additional precautions for HBsAg-positive
patients as noted previously, in combination with hepatitis B
vaccination, remain necessary for the continuing and success-
ful prevention of HBV transmission in chronic hemodialysis
settings.
The transmission of HCV infection among chronic hemodi-
alysis patients also might be related to failure to follow
routine hemodialysis unit precautions. Prevalence of anti-
body to HCV (anti-HCV) among chronic hemodialysis pa-
tients averages 10%, with some units reporting rates greater
than 60%.5 Risk factors for HCV infection among hemodialy-
sis patients have included history of blood transfusion,
volume of blood transfused, years on dialysis, and injection
drug use.3,14-16 Current screening and testing practices for
blood donors have reduced the threat associated with transfu-
sions to negligible numbers. Increasing years on dialysis has
been the risk factor most consistently reported as being
independently associated with higher rates of HCV infection.
As the number of years patients were on dialysis increased,
their prevalence of HCV infection increased from an average
of 12% to an average of 37%.3 This relationship was found
even for patients with no history of blood transfusion or
injecting drug use, suggesting that HCV might be transmitted
between patients in the hemodialysis setting. Further evi-
dence for such transmission can be derived from incidence
studies and outbreak investigations.15,16 In one study, an
annual incidence of approximately 3% was observed, and
none of the patients who seroconverted had received transfu-
sions or were injecting drug users.15
As with HBV, we believe that transmission of HCV among
hemodialysis patients results from apparent lack of awareness
or understanding by current hemodialysis staff of the differ-
ences between standard precautions and routine hemodialy-
sis unit precautions. Unlike HBV, however, additional precau-
tions (i.e., routine testing and cohorting) to prevent HCV
transmission are not necessary. When followed routinely,
hemodialysis unit precautions should be sufficient for prevent-
ing HCV transmission by preventing patients’ exposure to
blood-contaminated supplies, instruments, medication vials,
equipment, and hands of personnel. Periodic HCV testing for
infection control purposes currently is not recommended,
and isolation of HCV-positive hemodialysis patients is not
necessary. However, current guidelines do recommend HCV
testing for persons most likely to be infected with HCV
including chronic hemodialysis patients.17 Such testing pro-
vides the opportunity for appropriate medical management
and prevention counseling for HCV-infected persons.
The study by Mathurin et al. indicates that infection with
HBV or HCV significantly reduces the chances of survival for
renal transplant recipients. If we consider that at least some of
these patients contracted their infections during time spent in
hemodialysis units, then we have to admit our failure at not
having adequately protected them from these preventable
diseases. Individuals responsible for the care of chronic
hemodialysis patients should reacquaint themselves with the
recommendations for preventing blood-borne pathogen trans-
mission in this setting and ensure that they are performed.
SCOTT KELLERMAN, M.D., M.P.H.
MIRIAM J. ALTER, PH.D.
Hepatitis Branch, Division of Viral and Rickettsial Diseases
National Center for Infectious Diseases
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